Life sciences expands again in South Carolina see more
MycoWorks, a biotechnology company that specializes in mycelium-grown materials for use as sustainable, luxury-quality leather alternatives, today announced plans to establish operations in Union County. The company’s $107 million investment will create 400 new jobs.
Established in 2013, MycoWorks’ patented Fine Mycelium™ process produces materials including Reishi – a globally recognized breakthrough in materials science – that mimics the performance of animal leathers and lowers environmental impacts. The material offers creative solutions and new design possibilities for fashion and luxury brands while offering relief to supply chain constraints.
Located at 260 Midway Drive in Union, MycoWorks’ new facility will increase the company’s capacity to meet the fashion and luxury industries’ growing demand for its materials, including its flagship product Reishi.
Operations are expected to be online in early 2023. Individuals interested in joining the MycoWorks team should email firstname.lastname@example.org.
The Coordinating Council for Economic Development has approved job development credits related to this project.
"Deciding where to lay down roots was a big decision, but the partnership offered by state and local officials in combination with access to talent and amenities in the area made it easy. We look forward to growing a world class team and operation in Union County, South Carolina.” -MycoWorks Chief Operating Officer Doug Hardesty
“More and more innovative and sustainable companies are finding that South Carolina is an ideal location to establish operations, and we welcome MycoWorks to that growing roster of businesses. The $107 million investment and creation of 400 new jobs will make a significant impact in Union County and beyond.” -Gov. Henry McMaster
“We are at a time of great transformation among various industries, and companies like MycoWorks are paving the way in their arena. We welcome this groundbreaking business to South Carolina and look forward to watching them succeed for years to come.” -Secretary of Commerce Harry M. Lightsey III
“We are very excited to welcome MycoWorks to Union County. This project will greatly benefit the citizens of Union County through the jobs which will be created and the diversification of our industrial base within our community.” -Union County Supervisor Frank Hart
“We say the Upstate is where manufacturing and technology intersect, and MycoWorks is showing it by choosing to scale up in Union County. Their sustainable biotechnology products add high-tech opportunities to the region’s vibrant engineered materials ecosystem.” -Upstate SC Alliance President and CEO John Lummus
FIVE FAST FACTS
- MycoWorks is establishing operations in Union County.
- The $107 million investment will create 400 new jobs.
- MycoWorks is a biotechnology company that specializes in developing mycelium materials for use as sustainable, luxury-quality leather alternatives.
- Located at 260 Midway Drive in Union, S.C.
- Individuals interested in joining the MycoWorks team should email email@example.com.
Challenges in locating lab space impact Palmetto State as well as life sciences hotbeds see more
Office occupancy rates remain deflated across industries, but one type of workplace is in high demand: labs.
The big picture: A number of trends — in public health, American demographics and venture capital funding — are colliding to supercharge the life sciences industry.
Driving the news: U.S. office vacancy rates are at 17%, but lab vacancy rates are at 5%, according to a new report from the commercial real estate firm CBRE.
Money is pouring into life sciences companies. Venture capitalists are throwing money at gene editing and other promising therapies, at the same time that an aging American population is driving up health care spending.
- The annual amount of venture capital flowing to life sciences companies has roughly doubled since 2019 to a whopping $32 billion, per CBRE and CB Insights data in the report.
- Federal health care spending made up around 4% of GDP in 2006, but that's expected to swell to over 8% by 2040, according to the Congressional Budget Office.
What's happening: "This was a sector that was white-hot prior to the pandemic," says Jon Varholak, a vice chairman at CBRE who specializes in life sciences real estate. "The pandemic poured more gasoline on the fire."
- "People now more than ever are realizing we may need to be at the ready for something like this," he says.
- That's goading established life sciences companies to come up with innovative therapies and vaccines, and giving rise to startups that bring a fresh perspective to public health issues.
Biotech job openings are growing at their fastest pace on record, outpacing the notoriously hot tech sector, per a CBRE analysis of Bureau of Labor Statistics data.
Certain metro areas are benefiting from this boom more than others, according to the CBRE report.
- In Boston, lab vacancies are at 1.7%. Demand for lab space is so high that the city's "office market has become the envy of landlords across the country," the Wall Street Journal's Peter Grant writes.
- New York's lab vacancy rate is 1.1%, and San Francisco's is 2.6%.
And here's another new trend: Even though life sciences jobs have traditionally been located outside of cities — where there's ample inexpensive space for big labs and campuses — the strongest demand for lab space is actually in urban areas, says Ian Anderson, CBRE’s head of office research in the Americas.
- Employment growth between 2017 and 2020 was 25% in Middlesex County, Massachusetts — which is composed of the Greater Boston suburbs — but 35% in Boston proper.
- Growth was around 18% in San Mateo County, California, but nearly 92% in San Francisco.
- There's nearly 0% growth in Suffolk County, New York — which encompasses the Long Island suburbs — but over 25% in Manhattan.
The bottom line: "The whole industry is moving closer to where the intellectual capital is," Anderson says.
More than $750,000 investment will create 22 new jobs see more
COLUMBIA, S.C. – Belimed Life Science, Inc., a leading supplier of steam sterilizers and parts washers, today announced plans to establish operations in Charleston County. The more than $750,000 investment will create 22 new jobs.
Founded in 2019 in Switzerland, Belimed Life Science, Inc. provides Current Good Manufacturing Practices (cGMP) sterilizers and washers for the pharmaceutical and biotech markets. Specializing in machine process solutions for cleaning and sterilization, the company supplies customers on a global scale.
Located at 2154 N. Center Street in North Charleston, Belimed Life Science, Inc.’s new facility will provide product sales and support to the company’s North American customer base.
Hiring is underway, and individuals interested in joining the Belimed Life Science, Inc. team should visit the company’s careers website.
“As a manufacturer of products used in the manufacturing process of life-saving vaccines and drug therapies, Belimed Life Science is excited to open our first U.S. site in Charleston, South Carolina. As the pharmaceutical and biotech industries continue to innovate for the benefit of all of us, the need for our products and services will continue to increase requiring future growth of Belimed Life Science. What better place to begin than here in Charleston.” -Belimed Life Science, Inc. President Ken Blankenship
“Today's announcement by Belimed Life Science, Inc. is another win for our state's booming life sciences industry and is further testament that South Carolina is an ideal place for life science companies to locate. We celebrate the life-saving work of Belimed Life Science, Inc., and we look forward to their success in South Carolina. -Gov. Henry McMaster
“South Carolina's growing roster of life sciences companies proves that the state has the business environment in place to meet this industry's specific needs. And, with South Carolina's commitment to supporting research, training skilled workers and advancing supplier infrastructure, we’re an ideal location for companies like Belimed Life Science, Inc. to grow and thrive.” -Secretary of Commerce Harry M. Lightsey III
“When an international company like Belimed Life Science, Inc. invests in Charleston County, it is a testament to our people and community. We have the proven workforce and business-friendly climate that is attractive to life science companies.” -Charleston County Council Chairman Teddie Pryor
FIVE FAST FACTS
- Belimed Life Science, Inc. is establishing operations in Charleston County.
- The more than $750,000 investment will create 22 new jobs.
- Belimed Life Science, Inc. is a leading supplier of steam sterilizers and parts washers.
- Located at 2154 N. Center Street in North Charleston, S.C.
- Individuals interested in joining the Belimed Life Science, Inc. team should visit the company’s careers website.
Life sciences expands career opportunities for SC graduates see more
COVID caused pain and heartache and death across the world and here in the Lowcountry, but it also revealed some bright spots. One of those is the life sciences industry, which was responsible for diagnosing COVID, providing responses, and ultimately developing effective vaccines.
Coincidentally, the life sciences industry in South Carolina is itself on a growth spurt that was accelerated by the pandemic. The number of firms in the industry had doubled in the last four years, making it the fastest-growing industry sector in the state. The Darla Moore School of Business estimated its annual economic impact at $12 billion before the most recent spike.
Life sciences produce next-generation pharmaceuticals and vaccines; advanced medical devices, diagnostics, and testing; digital health; bioscience distribution; bio-agriculture and biomaterials; and biological solutions for advanced manufacturing.
Life sciences also encompass two areas of focus for the Lowcountry Graduate Center – advanced manufacturing and healthcare management. While the connection with healthcare is obvious, many people don’t realize that life science research and advanced manufacturing work symbiotically. Many life science innovations, like medical devices, require advanced manufacturing to produce, while life science innovations can power the process of advanced manufacturing itself.
Career Opportunities in Life Sciences
That means jobs, and not just for M.D.s and Ph.D.’s, but for technical college graduates and university biology and chemistry majors as well. The average life sciences position pays $79,000, according to the official state affiliate of the U.S. Biotechnology Innovation Organization, also referred to as SCBIO, the nonprofit organization dedicated to promoting the life sciences industry in S.C. Because workforce development is the primary challenge facing the industry, SCBIO is engaged in an initiative to promote the industry as a career path for students, guidance counselors, and parents at the K-12 level and in two- and four-year college.
Indeed, SCBIO is in the process of developing an industry-advocated life sciences curriculum for technical colleges that can prepare graduates for jobs in the field. Courses would cover manufacturing processes; safety and technical protocols like measurements and ISO standards; soft skills required for all workplaces; and the connections between the various life science components and the life-saving innovations they support.
“We want to get to students even sooner so we’re partnering with organizations that are already in schools to add more of the ‘S’ in STEM,” said Erin Ford, interim CEO at SCBIO. “If someone takes a course at Trident Tech, they can get a job paying $50,000 or more with health insurance while working on a product that helps people live better lives.”
The vector of life science development is different depending on the area of the state, with the Lowcountry showing strength in biotechnology, pharmaceutical, and manufacturing, says Ford.
Life Science Companies Need Space to Grow
Besides workforce development, the next big challenge constraining growth is space. Lab space at the new WestEdge development in downtown Charleston was fully subscribed when it opened and now developers are seeking new space. Clean labs are more complex and costly to retrofit and build than ordinary office or warehouse space.
Nonetheless, the firms keep coming – or starting – and the state has gotten behind the industry. As a critical step, it authorized and funded SCBIO as the state’s lead life sciences industry economic development organization.
Life science provides more than just more job growth: it provides diversification of an economy that 30 years ago relied heavily on a Navy base that packed up and left. Life sciences are more recession-resistant than automotive and aeronautics, two areas of manufacturing strength in the Lowcountry that respond to retail market demand. People never cease needing health innovations.
Recognizing that, the Charleston Regional Development Alliance (CRDA) and South Carolina Research Authority have backed the industry. CRDA was the first development authority in the state to build map out a strategic plan to attract and retain life science businesses.
Headwinds for Life Sciences in South Carolina
Sam Konduros of KOR Medical, a clinical cannabis firm launched by the Charleston-based diagnostic and testing company Vikor Scientific, says South Carolina and SCBIO have created a business climate conducive to the industry, and the health care and advanced manufacturing infrastructure have added tailwinds to its development. Citing Vikor’s growth from 45 employees to 450 during COVID, he says recruiting a talented workforce has not been a significant challenge so far. He notes the usual Charleston quality-of-life benefits – weather, beaches, history, and food, in addition to the growing vibrancy of the industry – as recruiting tools have contributed to the success.
Ford and Konduros see possible headwinds elsewhere for the industry. Roadways and other transportation infrastructure could use improvement, and housing availability and affordability are statewide issues. For example, the state’s franchise tax, now eliminated by 36 states, penalizes early-stage companies successfully raising venture capital before going to market. In an industry that often spends millions to earn FDA approval prior to commercialization, the tax is a burden, they say.
Life sciences among segments leading SC growth see more
When Commerce Secretary Harry Lightsey saw his first iPhone, he was seeing one of the first in the world. In 2007, it was one of only two.
At the time, he was the Southeast president of AT&T, in a room among the company’s top leadership.
When all eyes were on the company chairman, he reached into the pocket of his suit.
“He pulled out this object that none of us recognized and said, ‘This is one of two existing iPhones in the world. The other one is held by Stephen Jobs, and I’ve got this one. This device has convinced me that it is going to change the world, but I have no idea how it’s going to change the world, but I’m convinced it’s going to change the world,’” Lightsey recounted at Upstate SC Alliance’s midyear meeting, held at the Crowne Plaza Greenville Wednesday.
How today’s developments will mold the business landscape as we know it is yet to be seen, he said.
No one knows.
But, Lightsey assured the crowd of alliance investors, it’s shifting in the direction of ever-growing mobility, communications and biotech capabilities. And it’s shifting fast.
It’s South Carolina’s job to keep up and stay ahead, he said during one of his first public appearances in the Upstate since he took the secretary’s post.
“I do know this, that we have to be ready for change,” he said. “We have to be ready for the opportunities that the change is going to present to us. We shouldn’t view change as a threat or a concern, but as certainly something we can capitalize on.”
Much of the afternoon meeting focused on economic development victories of the past year within the life sciences, tech or R&D realms: a few vignettes from the 22 companies that moved to or expanded in the 10 counties in 2021 with Upstate SC Alliance’s assistance.
Upstate SC Alliance projects Pozyx, a Belgian information technology firm, and Oshkosh Defense’s manufacturing facility for the next generation mail truck held the spotlight, alongside BMW’s electrification efforts and Upstate biotech companies Zylo Therapeutics, Chartspan and Epica International.
Upstate SC Alliance’s announcements for the year thus far have prompted the creation of an expected 3,963 jobs and $930 million total investment.
“When many areas saw contractions in service, South Carolina’s manufacturing sector actually grew last year,” John Lummus, CEO and president of Upstate SC Alliance, said during the meeting. “And manufacturing and its need for engineering, technology and creative solutions will continue to drive our growth strategy moving forward. That’s why you’re seeing a stronger focus on innovation as a complement to our business recruitment program.”
He added that on the economic development announcement front, so far, 2021 has brought in three times the capital investment and twice the number of created jobs as 2019, especially in sectors bolstering enhanced mobility and health care services.
According to the group’s midyear report, the largest number of projects in the pipeline are in the engineered materials (263), automotive and transport (238), industrial manufacturing (155), life sciences (146) and aerospace and defense (144) fields. The first half of 2021 prompted 23 requests for information on economic development opportunities in the Upstate.
Domestic companies — 414 contacts to be exact — are the most likely, judging by the number of active contacts, to make the move to the Upstate in the months ahead.
International supply chains and travel may have been hampered by COVID-19 restrictions, but it didn’t completely derail progress, especially with the virtual playing field provided by a tectonic shift to Zoom conference rooms and continued in-person visits from leaders like Belgium’s Consul General in Atlanta, Michael Gerebtzoff.
The majority — almost 60% — of the companies that expanded in or moved to the area throughout 2021 were foreign-owned businesses: Deutsche Post DHL’s subsidiary DHL Supply Chain, Sweden’s Frauenthal Gnotec, Ireland’s E+I Engineering USA and China’s Gissing North America, just to name a few.
Looking forward, the United Kingdom, Germany, Canada, Spain, China, France, India, Belgium and Italy respectively are the hottest international sources for Upstate economic development prospects based off the number of active contacts.
“We have a lot of strengths and inherent advantages just because of who we are and where are,” Lightsey said. “But one of our main strengths is that we are a small state and we understand what it means to work together as a team. Commerce is a state agency that has supported the alliances’ growth and maturation of the alliances across the state, and the Upstate Alliance has certainly led the way, is something that’s incredible strength for our state: the ability to be able to work together for both our existing businesses, as well as those businesses that are looking to be partners with our state.”
South Carolina featured in JD Supra article see more
South Carolina has long been known for its colorful history, beautiful beaches and vibrant tourist industry. In recent decades, it has also come to be well known for its high-tech manufacturing with the likes of BMW, Boeing, Honda, Michelin, Samsung and Volvo, all locating large manufacturing facilities throughout the State. What you might not know is that South Carolina is also home to another rapidly growing high-tech industry—the Life Sciences industry.
The term Life Sciences is generally used to include companies in the fields of biotechnology, pharmaceuticals, biomedical technologies, life systems technologies, nutraceuticals, cosmeceuticals, food processing, environmental, and biomedical devices. The Life Sciences industry also includes organizations and institutions that devote the majority of their efforts in the various stages of research, development, technology transfer and commercialization, as well as the companies who support these entities.
According to SCBIO, the trade association which represents the Life Sciences industry in South Carolina, there are over 700 companies and businesses actively engaged in the Life Sciences industry in South Carolina and at least one Life Sciences organization is located in 42 of the State’s 46 counties. The economic impact of the Life Sciences industry is approaching $12 billion per year and is continuing to increase, according to a recent study. It is also estimated that the Life Sciences industry has created over 40,000 high paying jobs in South Carolina over the last several years, with an average annual salary of over $70,000.
The Life Sciences industry in South Carolina is very diverse. It includes companies ranging from small startups focusing on developing new technology like Okra Medical, to a unique genetic clinical and research institution like Greenwood Genetic Center, which has been serving the State for decades, to large established companies like Nephron Pharmaceuticals. Nephron is a pharmaceutical manufacturer and cGMP compliant 503(B) Outsourcing facility, and a global leader in the manufacture of generic respiratory medication that has rapidly expanded its manufacturing capacity and services over the last seven years. Nephron is owned and led by Lou Kennedy, whose vision and leadership have spurred the Company’s growth and success and have also made her one of the State’s most important business leaders, as well as an important thought leader in the Life Sciences industry.
South Carolina is a pro-business state that has worked diligently to attract large companies looking for a friendlier business climate from a tax and regulatory perspective. An additional driver for the growth of the Life Sciences industry is the existing ecosystem for Life Sciences, which is supported by the State’s three major research universities: University of South Carolina, Medical University of South Carolina and Clemson University as well as over ten additional universities and colleges in the State - from Furman University with its innovation program and nationally recognized chemistry department, to Newberry College launching new curriculum and a degree focused on pharmaceutical manufacturing. These universities and colleges further validate the increasing depth of the existing ecosystem and the positive impact it will have on strengthening the talent pool available to the Life Sciences industry. Other factors contributing towards this growth are the efforts of the South Carolina Department of Commerce and the South Carolina Research Authority, the strong system of hospitals and health care systems within the State, the support of various economic development alliances, the State’s expanding technical college system, the support of elected officials and the growth and leadership of SCBIO over the last several years.
SCBIO has spearheaded a series of joint private / public initiatives to promote the growth of the Life Sciences industry in South Carolina. These efforts include promoting statewide economic development strategies to attract Life Sciences companies to locate or relocate in South Carolina and consistently promoting and strengthening the existing ecosystem which allows established South Carolina Life Sciences organizations to collaborate, grow and flourish. In addition to its economic development efforts, SCBIO has integrated its efforts with the broader mission to transform and positively impact healthcare as evidenced by its unique alliances forged with the South Carolina Hospital Association, several large health systems and large payers like Blue Cross Blue Shield of South Carolina. For the past four years, SCBIO has been led by its CEO, Sam Konduros. Konduros has experience with economic development, operations of Life Sciences companies, developing start-up companies and most importantly—developing and implementing an ambitious strategic plan for the Life Sciences industry. During his time at SCBIO, Konduros has assembled a talented team. His vision and energy have fueled a rapid growth in membership and engagement and an increased in awareness and support for the Life Sciences industry across the State. Under his leadership, SCBIO significantly expanded its membership and quadrupled its revenues, while at the same time establishing itself as a powerful force for economic development and creating a new platform for Life Sciences companies to collaborate on innovations and research. Earlier this month, Konduros announced his departure from SCBIO to serve on the Board of Vikor Scientific, another successful company within the Life Sciences space in South Carolina that is rapidly expanding. He will also serve as CEO of a new health innovation company powered by artificial intelligence (AI) and blockchain technologies focusing on science personalized medicine strategies that will be a part of Vikor Scientific’s expanding portfolio of companies. SCBIO is conducting a national search for Konduros’ replacement and there is no doubt that the association and its members will continue to benefit from the momentum created over the last four years as it continues to push the Life Sciences industry forward.
The global COVID-19 pandemic presented a profound challenge to the Life Sciences industry as it disrupted the way business was conducted. The Life Sciences industry in South Carolina stepped up to these challenges and turned them into opportunities. Many Life Sciences companies pivoted from their existing strategic plans to address the needs of the State and Nation by providing assistance in key areas that became critical during the pandemic. Companies like Nephron Pharmaceuticals, Vikor Scientific, KIYATEC, Premier Medical Lab Services and others offered much needed expanded COVID-19 testing services inside and outside South Carolina. Others such as ZVerse, a digital manufacturing company, modified its business model to become one of the largest producers of reusable face shields for use during the pandemic and beyond. Over the last 12 months, they have produced millions of these reusable facemasks and have been recognized throughout the country for their efforts. Rhythmlink International, a medical device leader, donated thousands of masks and personal protective equipment (PPE) to hospitals and other healthcare providers across South Carolina. In addition, Milliken & Company boosted its production of biosmart fabrics used in scrubs and lab coats, which uses chlorine bleach-activated technology and molecular engineering to kill up to 99.9% of the bacteria and viruses it touches. Headquartered in Greenville, Vitalink Research was selected by Moderna to run its Phase III vaccine clinical trial, demonstrating national confidence in Life Sciences research operations in South Carolina. These are just a few examples of how South Carolina Life Sciences companies responded to the challenges of the COVID-19 pandemic and highlight why the Life Sciences industry is one of the fastest growing segments of South Carolina’s economy.
The future of the Life Sciences industry is bright in South Carolina. South Carolina has become an attractive place to develop and expand Life Sciences companies and there is great leadership within these companies. The rapid growth of Life Sciences is becoming more apparent to the public and media. In February 2021, Governor McMaster proclaimed February 15-19 as South Carolina Life Sciences Week in the Palmetto State. Our Life Sciences companies are leading the discussions of how to bring more Life Sciences manufacturing back to the U.S, including to South Carolina, and how to develop a domestic source of PPE and other parts of the supply chain. There is also increased collaboration on leveraging increased use of technology like telehealth and digital health to deliver health care services to rural and less developed areas using technology developed and perfected in South Carolina. SCBIO is also leading an effort to expand and improve the workforce to support Life Sciences companies. All signs point to a very bright future for the Life Sciences industry and South Carolina is just beginning to see the benefits of this growth and development.
Softbox a key player in battle to beat COVID see more
Softbox, a leading global innovator and provider of passive temperature control packaging solutions for the pharmaceutical, life science and cold chain logistics industries, is proud to support Pfizer in the distribution of Covid-19 vaccines through the supply of a high-performance temperature-controlled parcel shipper developed specifically for ultra-low temperature applications.
Softbox supported Pfizer with the development of the highly specialised and reusable ultra-low temperature (ULT) shipper to help them on the distribution of ultra-low temperature vaccines and storing them at Point of Use (POU) sites.
Ultra-Low Temperature vaccines, such as that developed by Pfizer – BioNTech, uses mRNA (messenger RNA) technology and must be stored at temperatures between -90°C to -60°C to ensure that the vaccine’s quality and efficacy is maintained. The ULT shipper is capable of maintaining the required temperature during shipping of Covid-19 vaccines between -90°C to -60°C for at least 10 days unopened.
The highly innovative shipper utilises high performance insulation materials, incorporated in a robust and reusable construction, in conjunction with dry ice, to ensure long term ultra-low temperature control. Based on current guidelines, the Softbox ULT Shipper can be opened twice a day, for up to three minutes at a time. This allows clinicians at Point of Use (POU) sites to access the vaccine vials required for each day’s immunisation clinics without exposing the remaining vaccine stored within the shipper to ambient temperatures, thus ensuring integrity of the vaccine is maintained.
When correctly managed, the ULT Shipper can be used to store vaccines for in excess of 30 days. Through a process called “Re-Icing” the dry ice in the Softbox ULT Shipper can be topped up ensuring maximum thermal protection of the highly temperature sensitive mRNA vaccines.
“Softbox’s extensive knowledge and experience in temperature control packaging solutions and the cold chain industry was the right choice for us. They immediately understood the unprecedented task at hand that was in front of us with the distribution of the vaccine, and quickly started to work with us to develop a unique packaging system that does not waste any precious vaccine and creates a seamless experience for customers.” said Tanya Alcorn, Vice President, Biopharma Global Supply Chain for Pfizer. “Their technical capabilities and innovative approach helped us achieve an excellent result in a very short period of time.”
Kevin Valentine, CEO of Softbox, said: “We are immensely proud to be playing such an important role in the fight against Covid-19. We worked extremely hard during 2020 to help Pfizer develop this highly innovative ULT shipper; establishing one of the world’s largest fleets of reusable temperature-controlled parcel shippers in the process and setting up two world-class service centres to support ULT shipper refurbishment.”
“It’s a huge honour to have the opportunity to support the distribution of these vital vaccines at the right temperature, maintain their integrity and help save millions of lives.”
For more information about Softbox visit: www.softboxsystems.com
Softbox is an award-winning temperature control packaging innovator that has been designing and producing high performance passive temperature control packaging solutions for over 20 years. We offer consistent quality to our clients from our strategically located global manufacturing sites throughout Europe, North America, Latin America, India and Asia Pacific.
We have formed long standing partnerships with the world’s leading pharmaceutical, clinical research, biotech and logistics companies, and apply innovative thinking to overcome the challenges that our clients face in managing the Cold Chain when shipping temperature sensitive clinical trial and commercialised products.
For more information about Softbox visit: www.softboxsystems.com
Vikor Scientific plans move to WestEdge in Charleston see more
Vikor Scientific, a biotech firm that provides targeted diagnostics to improve patient outcomes, is expanding and moving its headquarters into the 22 WestEdge building this spring.
The building is nearly complete and will include offices for both Vikor Scientific and members of senior management at MUSC Health, according to a news release.
Vikor, which is currently in offices in Suite 8 at 645 Meeting St. in downtown Charleston, provides medical professionals with diagnostic tools to improve treatments. The company takes a specimen and customizes molecular diagnostic panels to accurately detect and measure pathogens and antibiotic resistance within 12 to 24 hours.
“At Vikor’s new WestEdge location, together with South Carolina Research Authority, we’re creating a lab and office environment that people in Charleston have been craving for years,” Vikor co-founder Scotty Branch said. “Not only will our workforce feel good about going to work in a state-of-the-art facility looking out over a world-class city, we’re proud to invite scientists from across the country to visit our workspace.”
There are currently 53 employees at Vikor, and the company is hiring, the release said. The company’s WestEdge headquarters will include executive suites, sales and marketing teams, customer service, supply chain management and payer relations, plus clinicians, neuropharmacologists, medical specialists, researchers and scientists on multiple floors of the building.
Vikor co-founder and Medical University of South Carolina alumna Shea C. Harrelson said she is aware of potential collaboration opportunities with the neighborhood’s proximity to the medical district.
“We recently launched our research division, KOR Life Sciences, and we are interested in working with other scientists at MUSC to identify areas where synergy may be possible,” Harrelson said.
Michael Maher, CEO of The WestEdge Foundation Inc., said Vikor’s presence affirms the WestEdge vision. He said the neighborhood’s current and future living options, restaurants, retail, fitness, gathering and incubator spaces were developed with businesses like Vikor in mind.
The 22 WestEdge building will be the tallest multitenant office building on the peninsula and in the Charleston metro area when it opens, with 150,000 square feet of office and lab space, plus street-level space for cafes, restaurants and shopping, the release said.
Upon completion, the entire WestEdge project will encompass more than 3 million square feet of space on 60 acres along the Ashley River.
Husman launches new quality and compliance consultancy see more
Dr. David Husman has launched David Husman Consulting, LLC, a company that assists manufacturers with quality and compliance within the pharmaceutical, biopharmaceutical, and biotech industries. Services include quality program development, compliance auditing, remediation, and training.
Serving as president and principal consultant of the company, Dr. Husman holds a doctorate degree in biochemistry and has more than 30 years of diverse international experience in quality assurance, quality control, and regulatory affairs within the pharmaceutical, biopharmaceutical, and biotech industries. Before beginning David Husman Consulting, he was a principal consultant with Parexel Consulting. He also has served previously in leadership roles in quality assurance, quality control, and regulatory affairs.
Dr. Husman is certified in Good Manufacturing Practices and regulatory affairs. He earned his doctorate and bachelor’s degree in biochemistry from The Ohio State University in Columbus, Ohio. He is a long-term member of various professional organizations, including the Regulatory Affairs Professional Society, Parenteral Drug Association, American Society for Quality, and the S.C. Biotechnology Innovation Organization.
David Husman Consulting began accepting clients as of February 1, 2020. For more information, visit DavidHusmanConsulting.com.
Life sciences in South Carolina is big business -- and getting bigger by the day. Read why... see more
In this article published simultaneously in Charleston Business Magazine, Columbia Business Magazine and Greenville Business Magazine, SCBIO CEO Sam Konduros paints a picture of the diversity of the rapidly-growing life sciences industry, and why the future is exceedingly bright -- and getting brighter -- as the $11.4 billion industry soars to new heights across South Carolina.
Life sciences in South Carolina spans a diverse spectrum—from major pharmaceutical companies to globally known medical device companies.
It encompasses start-ups and early stage innovation companies and embraces prestigious research universities and acclaimed health care systems employing some of America’s finest minds. It includes research and medical labs, bioscience-related distribution, even Bio-Ag tied to the state’s historical agricultural segment. Click to read complete article...
A Columbia, SC-based biotech firm has introduced a new INTip solution with a proprietry design... see more
Columbia, SC – DPX Technologies announces a new INTip solution that utilizes a proprietary design for micro-elution dispersive solid phase extraction. DPX INTip solutions are designed to simplify sample preparation methods, and the μElution dSPE tip provides an automated solution for optimal sensitivity.
“The μElution dSPE tips were developed as an addition to the dSPE product line, that give our customers the ability to reduce elution volumes and increase sensitivity for downstream analysis,” said William E. Brewer, Ph.D., Founder and CEO of DPX Technologies. “DPX micro-elution methods eliminate solvent evaporation and reduce the challenges for sample preparation of high throughput, high sensitivity assays.”
Medical device manufacturer launching new operations in the Upstate; life science boom continues see more
Medical device manufacturer launching new operations in the Upstate
Monday, October 16, 2017
COLUMBIA, S.C. – Arthrex, Inc., a global orthopedic medical device company, headquartered in Naples, Fla., is launching new manufacturing operations in Anderson County. The $69 million capital investment is expected to create more than 1,000 new jobs over the next several years.
With a corporate mission aimed at helping surgeons treat patients better, Arthrex is a leader in new product development and medical education in orthopedics. The company is a pioneer in the field of arthroscopy and has developed more than 11,000 innovative products and surgical procedures to advance minimally invasive orthopedics worldwide.
Located at 5500 Highway 76 in Sandy Springs, S.C., Arthrex will be constructing a new 200,000-square-foot facility to manufacture its innovative orthopedic devices and implants. Hiring for the new positions should begin in the next 12 to 18 months, and interested applicants should visit the company’s careers page online(link is external).
The Coordinating Council for Economic Development has approved job development credits related to this project.
“Arthrex is pleased to bring its innovative spirit and unique culture to Anderson County, S.C. and we look forward to leveraging the outstanding work done in the area to prepare future employees for high-level manufacturing jobs.” –Arthrex Vice President of Manufacturing Andy Owen
“South Carolina’s business-friendly climate continues to attract companies in every industry, and we’re proud to welcome Arthrex, Inc. to our growing business community. This a milestone for Anderson County, and we can’t wait to see the difference these jobs will make in the region.” –Gov. Henry McMaster
“Not only does our state excel in manufacturing, we’re also increasingly becoming a top choice for companies in the life sciences sector. Arthrex joins an impressive roster of life sciences firms that call South Carolina home, and we look forward to watching them grow in Anderson County for years to come.” –Secretary of Commerce Bobby Hitt
“We are absolutely thrilled to begin our partnership with Arthrex. Their precision medical products are used by medical professionals around the globe, and the fact that our citizens have been chosen to make them says volumes about the quality of our workforce as well as the skills training we provide.” –Anderson County Council Chairman Tommy Dunn
“This announcement takes our county in an exciting direction. Our goal of establishing a diverse economic base for our citizens is becoming a reality. The presence of this world-class company in our community speaks for who we are in Anderson, and we welcome them with open arms.” –Anderson County Councilman Tom Allen, District Four
FIVE FAST FACTS
- Arthrex is launching new manufacturing operations in Anderson County.
- $69 million capital investment to create more than 1,000 new jobs.
- Arthrex is a leading manufacturer of orthopedic medical devices.
- Located at 5500 Highway 76 in Sandy Springs, S.C., the company will be constructing a new 200,000-square-foot facility to manufacture its innovative orthopedic devices and implants.
- Hiring for the new positions should begin in the next 12 to 18 months, and interested applicants should visit the company’s careers page online.
Growth of South Carolina's Life Sciences, Upcoming Events featured in Statewide Radio Interview by SCBIO's Erin FordSCBIO's Erin Ford is featured statewide on South Carolina Business Review see more
Life sciences is one of the fastest-growing segments in South Carolina's economy, with an annual economic impact exceeding $11 billon. SCBIO Vice President Erin Ford is the featured guest on this edition of South Carolina Business Review, the popular business news program hosted by Mike Switzer airing on South Carolina Public Radio across the Palmetto State. Click here to hear Erin's comments about the life sciences industry, as well as a major upcoming event next week in Columbia.
South Carolina's life sciences industry is booming. Read on for details... see more
From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming. The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries. Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.
Lonza's $46 million investment expected to create new jobs in Greenwood, SC see more
Lonza, one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets, today announced plans to expand operations in Greenwood County. The company is investing $46 million over the next five years and is expected to generate 30 new jobs as a result.
Headquartered in Basel, Switzerland, Lonza harnesses science and technology to create products that enhance the overall quality of life for patients and consumers around the world. Through its acquisition of Capsugel in July 2017, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms.
Lonza’s Greenwood County operations, which are located at 535 North Emerald Road in Greenwood, S.C., produce empty capsules and finished dosage forms for the global biopharma and consumer health and nutrition markets. To expand, the company is adding approximately 50,000 square feet of new manufacturing space, which will enable the firm to produce key nutritional ingredients, among other projects.
With construction expected to be completed in the second quarter of 2019, hiring for the new positions will take place starting in mid-2018. Those interested in joining the Lonza team should visit the company’s careers page online(link is external).
The Coordinating Council for Economic Development has approved job development credits, as well as a $300,000 Set Aside grant to Greenwood County to assist with the costs of site work and infrastructure improvements.
“Lonza is making a significant investment in our operations in Greenwood, further demonstrating our commitment to providing high-quality products and services to our customers worldwide. Greenwood County is rich with talented, skilled individuals who will enhance our global and regional footprint, particularly in the area of consumer health and nutrition.” –Lonza Specialty Ingredients COO Sven Abend
“South Carolina’s workforce continues to demonstrate unmatched excellence; and, as a result, global companies like Lonza are growing and thriving here. I look forward to seeing all that these new positions will be able to produce and achieve in the years to come.” –Gov. Henry McMaster
“The Palmetto State’s life sciences industry continues to expand, showcasing South Carolina’s ability to produce a variety of advanced products. We congratulate Lonza and look forward to their continued success in Greenwood County.” –Secretary of Commerce Bobby Hitt
“Lonza has been an excellent job provider and a source of economic prosperity for Greenwood County. Their new expansion is exciting and encouraging, as it means their good work will continue to produce positive results for people locally and globally.” –Greenwood County Council Chairman Steve Brown
“We congratulate our friends at Lonza on today’s expansion announcement. Lonza’s continued growth within Greenwood County speaks to the company’s dedication and commitment to the area and the future of life sciences in South Carolina.” –Greenwood Partnership Alliance Chair Dr. Kristin Manske
FIVE FAST FACTS
- Lonza is expanding operations in Greenwood County.
- $46 million investment to create 30 new jobs.
- Lonza designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries.
- The company is adding 50,000 square feet to its Greenwood County facility, which is located at 535 North Emerald Road in Greenwood, S.C.